OAM
IMDX

Oxford Asset Management’s Insight Molecular Diagnostics IMDX Stock Holding History

Oxford Asset Management’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,413
Closed -$64K – 942
2019
Q4 		$64K Buy
+1,413
New +$51K ﹤0.01% 1653
2019
Q3 		– Sell
-665
Closed -$33K – 1880
2019
Q2 		$33K Buy
+665
New +$55.3K ﹤0.01% 1648

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Oxford Asset Management's IMDX Position: Q1 2020 in Review

Oxford Asset Management sold out of Insight Molecular Diagnostics (IMDX) in Q1 2020, closing a stake of 1,413 shares — an estimated $64K sold.

Oxford Asset Management first reported a position in IMDX in Q2 2019 and held it in 2 quarters. The position peaked at $64K in Q4 2019. 56 funds tracked by Wall St. Rank hold IMDX as of Q1 2020.

  • Oxford Asset Management reported no remaining Insight Molecular Diagnostics position as of Q1 2020 after selling out during the quarter.
  • Oxford Asset Management sold 1,413 Insight Molecular Diagnostics shares in Q1 2020, an estimated $64K.
  • Oxford Asset Management first reported a position in Insight Molecular Diagnostics in Q2 2019 and held it in 2 quarters.
  • Oxford Asset Management's Insight Molecular Diagnostics position peaked at $64K in Q4 2019.
  • 56 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.